Articles by Heshmat R (6)

Sub-chronic toxicity study of a novel herbal-based formulation (Semelil) on dogs

Farzamfar B, Abdollahi M, Ka`abinejadian S, Heshmat R, Shahhosseiny MH, Novitsky Y.A and Farhadi M

DARU 16 ( S1 ): 15 - 19 , 2008

In vivo and in vitro genotoxicity studies of Semelil (ANGIPARS™)

Khorram Khorshid HR, Sadeghi B, Heshmat R, Abdollahi M, Salari P, Farzamfar B and Madani SH

DARU 16 ( S1 ): 20 - 24 , 2008

Assessment of maximum tolerated dose of a new herbal drug, Semelil (ANGIPARS™) in patients with diabetic foot ulcer: A Phase I clinical trial

Heshmat R, Mohammad K, Mohajeri Tehrani MR, Tabatabaie Malazy O, Keshtkar AA, Gharibdoust F and Larijani B

DARU 16 ( S1 ): 25 - 30 , 2008

Effects of intravenous Semelil (ANGIPARS™) on diabetic foot ulcers healing: A multicenter clinical trial

Larijani B, Heshmat R, Bahrami A, Delshad H, Ranjbar Omrani G, Mohammad K, Heidarpour R, Mohajeri Tehrani MR, Kamali K, Farhadi M, Gharibdoust F and Madani SH

DARU 16 ( S1 ): 35 - 40 , 2008

Clinical application of oral form of ANGIPARS™ and in combination with topical form as a new treatment for diabetic foot ulcers: A randomized clinical trial

Bahrami A, Kamali K, Ali-Asgharzadeh A, Hosseini P, Heshmat R, Khorram Khorshid HR, Gharibdoust F, Madani SH and Larijani B

DARU 16 ( S1 ): 41 - 48 , 2008

Intravenous Semelil (ANGIPARS™) as a novel therapy for pressure Ulcers: A randomized clinical trial

Shamimi Nouri K, Heshmat R, Karimian R, Nasli E, Larijani B, Novitsky YA, Farhadi M and Gharibdoust F

DARU 16 ( S1 ): 49 - 53 , 2008